Exelixis, Inc. (NASDAQ:EXEL) EVP Dana Aftab Sells 1,162 Shares

Exelixis, Inc. (NASDAQ:EXEL) EVP Dana Aftab sold 1,162 shares of Exelixis stock in a transaction on Wednesday, October 30th. The shares were sold at an average price of $31.40, for a total transaction of $36,486.80. Following the transaction, the executive vice president now owns 498,945 shares in the company, valued at $15,666,873. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link.

Dana Aftab also recently made the following trade(s):

• On Monday, August 12th, Dana Aftab sold 20,883 shares of Exelixis stock. The stock was sold at an average price of $27.06, for a total transaction of $565,093.98.
• On Wednesday, August 7th, Dana Aftab sold 95,000 shares of Exelixis stock. The stock was sold at an average price of $25.00, for a total transaction of $2,375,000.00.

Exelixis Price Performance

Shares of NASDAQ:EXEL opened at $34.12 on Friday. Exelixis, Inc. has a one year low of $19.20 and a one year high of $34.45. The company has a 50 day moving average of $27.13 and a 200-day moving average of $24.29. The stock has a market cap of $9.74 billion, a price-to-earnings ratio of 21.87, a P/E/G ratio of 0.69 and a beta of 0.54.

Exelixis (NASDAQ:EXEL) last issued its quarterly earnings results on Tuesday, October 29th. The biotechnology company reported $0.40 EPS for the quarter, topping the consensus estimate of $0.36 by $0.04. Exelixis had a net margin of 22.43% and a return on equity of 20.99%. The company had revenue of $539.50 million during the quarter, compared to analysts’ expectations of $490.31 million. During the same quarter in the previous year, the company earned $0.10 EPS. Exelixis’s revenue was up 14.3% on a year-over-year basis. Equities research analysts anticipate that Exelixis, Inc. will post 1.59 earnings per share for the current year.

Analysts Set New Price Targets

A number of research analysts have issued reports on EXEL shares. Oppenheimer reissued an “outperform” rating and set a $29.00 target price on shares of Exelixis in a research note on Tuesday, July 30th. BMO Capital Markets increased their target price on shares of Exelixis from $29.00 to $36.00 and gave the company an “outperform” rating in a research note on Wednesday. Wells Fargo & Company increased their target price on shares of Exelixis from $32.00 to $36.00 and gave the company an “overweight” rating in a research note on Wednesday. Royal Bank of Canada restated an “outperform” rating and set a $34.00 price target on shares of Exelixis in a report on Wednesday. Finally, HC Wainwright reiterated a “buy” rating and issued a $29.00 price objective on shares of Exelixis in a research note on Wednesday, September 18th. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating, fourteen have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $31.44.

Institutional Investors Weigh In On Exelixis

Several institutional investors have recently modified their holdings of the business. V Square Quantitative Management LLC acquired a new position in Exelixis during the third quarter valued at approximately $30,000. Park Place Capital Corp acquired a new position in Exelixis during the second quarter valued at approximately $45,000. GAMMA Investing LLC grew its holdings in Exelixis by 107.9% during the second quarter. GAMMA Investing LLC now owns 2,006 shares of the biotechnology company’s stock valued at $45,000 after purchasing an additional 1,041 shares during the period. EntryPoint Capital LLC grew its holdings in Exelixis by 537.2% during the first quarter. EntryPoint Capital LLC now owns 2,071 shares of the biotechnology company’s stock valued at $49,000 after purchasing an additional 1,746 shares during the period. Finally, Capital Performance Advisors LLP acquired a new position in Exelixis during the third quarter valued at approximately $61,000. Institutional investors and hedge funds own 85.27% of the company’s stock.

Exelixis Company Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.